How much does ponatinib cost?

Ponatinib, trade nameIclusig, is a potent third-generation BCR-ABL tyrosine kinase inhibitor. This drug has shown significant efficacy in the treatment of patients who are resistant or intolerant to tyrosine kinase inhibitors, especially in patients with chronic phase, accelerated phase or blast phase chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib effectively inhibits BCR-ABL kinase, including in patients with the T315I mutation, which often leads to resistance to traditional TKIs. In clinical trials, ponatinib has demonstrated good therapeutic effects in patients with CML and Ph+ ALL, making this drug an important treatment option for these patients.

However, the use of ponatinib also comes with certain risks. The U.S. Food and Drug Administration (FDA) once required manufacturers to stop sales and promotion and conduct a risk-benefit assessment because of its possible side effects such as life-threatening blood clots and severe stenosis. Later, after adding a black box warning and restricting indications, it was approved for marketing again. Therefore, when using ponatinib, the patient's response needs to be closely monitored and dose adjustments or discontinuation made as appropriate.

What is gratifying is that ponatinib was successfully launched in China last month. However, due to the short time on the market, it may still be difficult for patients to purchase it directly in China. For patients in need, you can consider learning about overseas purchasing methods. Taking the specifications of15mg*30 tablets as an example, the price of the original drug in Hong Kong is about NT$23,000. At the same time, generic drugs are also a more economical choice. For example, the price of Bangladesh's Beacon Pharmaceutical is about 3,800 yuan, the price of Bangladesh's Everest Pharmaceutical is as low as about 1,650 yuan, and the version of Lucius in Laos is extremely cost-effective, priced at less than 1,000 yuan.

In general, ponatinib is an effective anti-cancer drug that provides new treatment opportunities for patients with drug-resistant or intolerant CML and Ph+ ALL, but it also needs to be used with caution to ensure patient safety.